BIONDD®: Oral delivery of biologics from a small, easy-to-swallow capsule, in place of the injection.
Biograil · pre-clinical stage · Roskilde, Denmark
Biograil is a pre-clinical stage pharmaceutical company working to transform injectable medicines into convenient oral capsules.
BIONDD® is the platform behind it. A device sits inside a conventional capsule and delivers the drug into tissue after the capsule is swallowed, so biologics that today depend on a needle could be taken by mouth.
→How BIONDD worksFrom capsule to tissue in four steps
Drawn from Biograil's own description of the mechanism. Scroll to follow the device.
- SwallowedA conventional and small, easy-to-swallow capsule carries the device and the biologic.
- ReleasedThe capsule dissolves in the stomach and releases a device with a spring-loaded grabbing mechanism.
- AttachedThe device attaches to the stomach wall, releasing medication into the tissue for systemic distribution.
- PassedAfter drug delivery, the bio-compostable device passes through the GI tract.
One device, several classes of biologic
BIONDD is being developed as a platform for oral delivery of biologics, including peptides, antibodies and RNAs. Biograil works with pharma partners on the compounds that would benefit.
Peptides
Named by Biograil as part of the platform scope for oral delivery.
Platform scopeAntibodies
Large molecules named by Biograil as part of the platform scope.
Platform scopeRNAs
Nucleic-acid therapeutics named by Biograil as part of the platform scope.
Platform scope
Financing
“Excellent to see such strong support from existing internal investors.” Karsten Lindhardt, CEO, on the EUR 20 million round, November 2026
- Round
- EUR 20 million
- Investors
- Verve Ventures, Megatrend Invest, HTGF via its HTGF Opportunity fund
- Use of funds
- Preparing Phase 1 clinical testing of BIONDD®: non-clinical GLP studies and a GMP manufacturing process
- Next
- A larger financing is expected in 2027
Work with Biograil
Pharma partners
Licensing and co-development of BIONDD® with your biologic. Talk to the team in Roskilde about your compound.
→Start a partnering talkInvestors
Backed by Verve Ventures, Megatrend Invest and HTGF, with a larger round expected in 2027.
→Investor informationCareers
Analytical Development & CMC role in Roskilde. Applications until 1 December 2026.
→View the open role